がん免疫療法に対する原発性,適応性,および獲得性抵抗性
Padmanee Sharma1, Siwen Hu-Lieskovan2, Jennifer A Wargo3
1Department of Genitourinary Medical Oncology and Immunology,The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Cell
|February 11, 2017
まとめ
癌の免疫療法は,転移した癌に対して持続的な反応を提供します. 免疫回避メカニズムの理解は 抵抗を克服し 患者のがん治療結果を改善する鍵です
科学分野:
- 腫瘍学
- 免疫学
背景:
- 癌の免疫療法は,様々な組織学における転移性癌の治療において有望であることが示されています.
- しかし,耐性メカニズムの理解が限られているため,より広範な臨床応用が困難です.
研究 の 目的:
- 免疫系とがん細胞の相互作用を 病気の進行過程で調べる
- 癌の免疫療法に対する耐性の基礎となる分子メカニズムを特定する.
主な方法:
- この研究では 癌と免疫系の関係が 進化していることが検討されています
- 癌細胞が利用する 免疫回避戦略に焦点を当てています
- 分子抵抗経路の解明が中心です
主要な成果:
- 癌の免疫療法は,転移性疾患において持続的な反応を引き起こす可能性があります.
- 免疫逃避は癌の進行と転移の重要な要因です.
- 耐性メカニズムの理解は 治療の開発に不可欠です
結論:
- 免疫療法に対する耐性メカニズムの理解を深めることが不可欠です.
- これらのメカニズムをターゲットにすることで 改善された臨床戦略を実現できます
- この研究は,がんの免疫療法における患者の成果を向上させることを目的としています.
関連する概念動画
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines
1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Cytotoxic T Cells-mediated Immune Response
7.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.7K
Cell-mediated Immune Responses
85.4K
Overview
85.4K


